SlideShare a Scribd company logo
1 of 29
Download to read offline
///////////
Investor
Conference Call
Q2 2022 Results
August 4th, 2022
Werner Baumann, CEO
Wolfgang Nickl, CFO
This presentation may contain forward-looking statements based on current assumptions and forecasts
made by Bayer management.
Various known and unknown risks, uncertainties and other factors could lead to material differences
between the actual future results, financial situation, development or performance of the company and the
estimates given here. These factors include those discussed in Bayer’s public reports which are available
on the Bayer website at http://www.bayer.com/.
The company assumes no liability whatsoever to update these forward-looking statements or to conform
them to future events or developments.
Guidance at constant currencies, not including portfolio divestitures if not mentioned differently.
Cautionary Statements Regarding Forward-Looking Information
Bayer Q2 2022 Investor Conference Call /// August 4th, 2022
2
///////////
Business Update
Werner Baumann, CEO
Q2 2022 Results
We Raise Our Guidance Based on Half Year Performance
Bayer Q2 2022 Investor Conference Call /// August 4th, 2022
4
1 Growth
Innovation
3
2 Resilience
Gas Exposure and Mitigation Measures
Bayer Q2 2022 Investor Conference Call /// August 4th, 2022
5
2nd Order Impact (INDIRECT)
Own Operations (DIRECT)
No material financial impact for FY 2022 expected
1 Including electricity, gas, coal, oil, utilities + steam
Preparations to completely mitigate own gas exposure well advanced
• Technical readiness to reduce natural gas dependency
• Switch to alternative and renewable energy sources
• Building up inventory where possible
• Fixed contract pricing
Systemic risk from disrupted operations of suppliers and contract manufacturers
• Pro-active risk management to increase supply chain resilience
Energy & Utilities Footprint 1 (2021)
~97%
Other
CoGS
~3%
Energy Costs
~50%
RoW
EUR
450m1
~35%
~15%
Other EMEA
///////////
Wolfgang Nickl, CFO
Q2 2022 Results
Group Performance & Outlook
Sustained Growth and Earnings Dynamics in Q2
Bayer Q2 2022 Investor Conference Call /// August 4th, 2022
7
EBITDA
2.577
3.349
Q2'21 Q2'22
10.854
12.819
Q2'21 Q2'22
In million €, before special items
In million €, ∆% yoy In €, Cont. Operations
+18%
(+10% cpa)
+30%
26.1%
23.7%
In million €
Sales Core EPS Free Cash Flow
EBITDA Margin before special items, cpa = currency and portfolio adjusted
1.152 1.140
Q2'21 Q2'22
1,61
1,93
Q2'21 Q2'22
+20%
FX tailwind of €915m FX tailwind of €300m (+0.5%pts)
-1%
2021 baseline incl.
extraordinary gains in core
financial result
2021 baseline incl.
lower incentive payouts
• Herbicides (+51%) with continued favorable
market dynamics
• Corn S&T (+10%) supported by the launch
of high-performing new hybrids globally
• Soy S&T (-16%) impacted by reduction of
excess seed sales and exit of Argentina
business; flat YTD on a comparable basis
• Fungicides up (+4%), particularly in EMEA
and LATAM
• Substantially improved margin compared to
low prior year basis
1.018
1.749
Q2'21 Q2'22
5.021
6.461
Q2'21 Q2'22
Sales
In million €, ∆% yoy, cpa.
Bayer Q2 2022 Investor Conference Call /// August 4th, 2022
8
Volume
-2%
Currency
+12%
Price
+20%
Portfolio
0%
Sales EBITDA
In million €, ∆% yoy In million €, before special items
Key Messages
+29%
(+17% cpa)
EBITDA Margin before special items, cpa = currency and portfolio adjusted
27.1%
20.3%
+72%
Crop Science: Continued Strong Growth
Sales growth rates in Key Messages cpa = currency and portfolio adjusted
• EyleaTM (+12%) with increases in all regions
• XareltoTM (-6%) impacted by volume-based
procurement in China and loss of exclusivity
in Brazil
• Strong performance of new products:
NubeqaTM sales more than doubled, ongoing
dynamic launch momentum for KerendiaTM
• Continued investments in launches and
roll-outs
• Margin at constant currencies on par with
prior year
1.409
1.478
Q2'21 Q2'22
4.494
4.818
Q2'21 Q2'22
Sales
In million €, ∆% yoy, cpa.
Pharmaceuticals: Driving Launch Products
Bayer Q2 2022 Investor Conference Call /// August 4th, 2022
9
Sales EBITDA
In million €, ∆% yoy In million €, before special items
Volume
+2%
Currency
+5%
Price
-0%
Portfolio
0%
Key Messages
+7%
(+2% cpa)
30.7%
31.4%
EBITDA Margin before special items, cpa = currency and portfolio adjusted
5%
Sales growth rates in Key Messages cpa = currency and portfolio adjusted
278
330
Q2'21 Q2'22
1.290
1.496
Q2'21 Q2'22
Sales
In million €, ∆% yoy, cpa.
Consumer Health: Sustained Growth Across All Regions
Bayer Q2 2022 Investor Conference Call /// August 4th, 2022
10
Sales EBITDA
In million €, ∆% yoy In million €, before special items
Key Messages
Volume
+3%
Currency
+9%
Price
+4%
Portfolio
+1%
+16%
(+7% cpa)
22.1%
21.6%
EBITDA Margin before special items, cpa = currency and portfolio adjusted
+19%
• Allergy & Cold (+17%) driven by higher
number of cold incidences
• AsteproTM launch preparation and trade
inventory build up
• Nutritionals (-4%) consolidate at very high
level
• Digestive Health (+13%) with sustained
demand for MiraLAX in North America
• Earnings benefitted from strong topline,
continuous spending discipline and ability
to pass on cost increases
Sales growth rates in Key Messages cpa = currency and portfolio adjusted
Sales Growth
2022
(cpa)
EBITDA-margin
2022
(before special items)
~ 13% ~ 27%
3% - 4% ~ 32%
6% - 7% 22% - 23%
FY 2022: Increased Outlook for Crop Science and Consumer Health
Bayer Q2 2022 Investor Conference Call /// August 4th, 2022
11
Sales Growth
2022
(cpa)
EBITDA-margin
2022
(before special items)
Crop Science ~ 7% 25% - 26%
Pharmaceuticals 3% - 4% ~ 32%
Consumer Health 4% - 5% 22% - 23%
cpa = currency and portfolio adjusted
As of Mar ‘22
OLD
As of Aug ‘22
NEW
ES divestment effects not included;
at constant currencies
(based on 2021 average Actual rates)
FY 2022: Group Outlook Raised
Bayer Q2 2022 Investor Conference Call /// August 4th, 2022
12
Net Sales
EBITDA margin
(before special items)
Core EPS
Free cash flow
Net financial debt
~ €46bn
~ 26%
~ €7.00
~ €2.0 -
€2.5bn2
~ €33 - 34bn
At constant currencies Estimated currency impact1
~ + €3bn
~ + €0.40
~ + €1.3bn
~ - 0.4%pts
not material
1 Currency assumptions based on month-end June 2022 spot rates (1 EUR=) 1.04 USD, 5.42 BRL, 6.97 CNY, 141.63 JPY, 56.38 RUB. Impact calculated as difference to constant currencies.
2 Incl. net settlement payments of approx. -€2.5bn
€47bn –
€48bn
26 - 27%
~ €7.30
~ €2.5bn2
~ €33 - 34bn
At constant currencies
NEW
(as of Aug ’22)
OLD
(as of Mar ’22)
ES divestment effects not included;
at constant currencies
(based on 2021 average Actual rates)
///////////
Investor
Conference Call
Q2 2022 Results
August 4th, 2022
Werner Baumann, CEO
Wolfgang Nickl, CFO
FY 2022: Other Group KPIs Outlook
Bayer Q2 2022 Investor Conference Call /// August 4th, 2022
14
Special items (EBITDA)
Depreciation and amortization (clean)
of which for intangible assets (clean)
Core financial result
Core tax rate
Reconciliation (cEBITDA)
~ -€1.0bn
~ €3.6bn
~ €2.1bn
~ -€1.8bn
~ 23%
~ -€700m
1 Currency assumptions based on month-end June 2022 spot rates (1 EUR=) 1.04 USD, 5.42 BRL, 6.97 CNY, 141.63 JPY, 56.38 RUB. Impact calculated as difference to constant currencies
~ -€1.0bn
~ €3.6bn
~ €2.1bn
~ -€1.5bn
~ 23%
~ -€500m -
-€600m
NEW
(as of Aug ’22)
At constant currencies
OLD
(as of Mar ’22)
Expected currency impacts:1
Not material
At constant currencies
ES divestment effects not included;
at constant currencies
(based on 2021 average Actual rates)
Q2 2022: Core EPS to EPS Bridge
Bayer Q2 2022 Investor Conference Call /// August 4th, 2022
15
in €
Q2 2021 Q2 2022
Net Sales 10,854 12,819
EBITDAbefore special items 2,577 3,349
Special items -3,468 -698
Reported EBITDA -891 2,651
Depreciation & Amortization -1,390 -2,482
Reported EBIT -2,281 169
Amortization and impairment losses / loss reversals on
intangible assets
1,025 2,082
Special items (EBITDA) 3,468 698
Other 3 7
Core EBIT 2,215 2,957
Core financial result (before special items) -115 -565
Core EBT 2,100 2,392
Taxes (before special items) -511 -490
Core tax rate 24.4% 20.6%
Minorities -7 -9
Core Net income 1,582 1,893
No. of shares (m) 982.4 982.4
Core EPS (€) 1.61 1.93
Income from cont. Operations (after income taxes,
w/o non-controlling interest)
-2,335 -298
Income from discont. Operations (after income taxes) 0 0
Net income -2,335 -298
EPS from cont. and discont. Operations (€) -2.38 -0.30
Delta Working Capital 3,749 351
Operating Cash Flow (cont. operations) 1,997 2,104
Free cash flow 1,152 1,140
CapEx and leasing, cont. Operations -493 -550
Q2 2022: Key KPIs Bayer Group
Bayer Q2 2022 Investor Conference Call /// August 4th, 2022
16
Guidance at ~23% for FY 2022
2
2
3
Reversal Glyphosate Litigation Provision in Other
WoC in Q2 2021
3
Glyphosate Litigation Provision in Q2 2021,
additional PCB Litigation Provision in Q2 2022
1
1
Q2 2022: Key KPIs by Division
Bayer Q2 2022 Investor Conference Call /// August 4th, 2022
17
[€ million] Q2'21 Q2'22 Q2'21 Q2'22 Q2'21 Q2'22 Q2'21 Q2'22 Q2'21 Q2'22
Sales 5,021 6,461 4,494 4,818 1,290 1,496 49 44 10,854 12,819
Sales by region:
Europe / Middle East / Africa 1,003 1,255 1,774 1,878 419 462 49 44 3,245 3,639
North America 2,532 3,056 1,032 1,149 503 611 -1 1 4,066 4,817
Asia / Pacific 627 704 1,460 1,550 214 238 1 2,302 2,492
Latin America 859 1,446 228 241 154 185 0 -1 1,241 1,871
EBITDA -2,496 1,701 1,564 1,559 269 327 -228 -936 -891 2,651
Special items -3,514 -48 155 81 -9 -3 -100 -728 -3,468 -698
EBITDA before special items 1,018 1,749 1,409 1,478 278 330 -128 -208 2,577 3,349
EBITDA margin before special items 20.3% 27.1% 31.4% 30.7% 21.6% 22.1% • • 23.7% 26.1%
EBIT -3,483 -258 1,312 1,206 187 239 -297 -1,018 -2,281 169
Special items -3,945 -1,369 152 -10 -8 -3 -100 -729 -3,901 -2,111
EBIT before special items 462 1,111 1,160 1,216 195 242 -197 -289 1,620 2,280
EBIT margin before special items 9.2% 17,2% 25.8% 25.2% 15.1% 16.2% • • 14.9% 17.8%
Operating cash flow, continuing 1,734 2,551 570 35 165 116 -472 -598 1,997 2,104
D&A and Write-downs 987 1,959 252 353 82 88 69 82 1,390 2,482
Employees at end of period 33,196 34,311 39,830 40,863 10,608 11,027 15,805 15,713 99,439 101,914
Group
Crop Science Pharmaceuticals Consumer Health Reconciliation
HY1 2022: Group Overview
Bayer Q2 2022 Investor Conference Call /// August 4th, 2022
18
EBITDA
6.695
8.600
HY1'21 HY1'22
23.182
27.458
HY1'21 HY1'22
In million €, before special items
In million €, ∆% yoy In €, Cont. Operations
+18%
(+12% cpa)
+29%
31.3%
28.9%
In million €
Sales Core EPS Free Cash Flow
EBITDA Margin before special items, cpa = currency and portfolio adjusted
-2.074
-47
HY1'21 HY1'22
4,20
5,46
HY1'21 HY1'22
+30%
FX tailwind of €1,444m FX tailwind of €367m (-0.3%pts) Core Tax Rate below FY
Significantly lower net settlement
payouts
• Double-digit sales growth across all regions
• Herbicides (+56%) with stronger pricing in light
of continued tight supply and strong demand
for glyphosate-based herbicides
• Corn S&T (+10%) supported by the launch of
high-performing new hybrids globally
• Soy S&T (-8%) impacted by reduction of
excess seed sales and exit of Argentina soy
business, flat YTD on a comparable basis
• Fungicides (+12%) mostly driven by volume in
EMEA and LATAM
• Earnings benefitting as value-based pricing in
a strong market and efficiency measures
outpace significant cost inflation
3.466
5.418
H1'21 H1'22
11.667
14.908
H1'21 H1'22
Sales
In million €, ∆% yoy, cpa.
Bayer Q2 2022 Investor Conference Call /// August 4th, 2022
19
Volume
+2%
Currency
+8%
Price
+18%
Portfolio
-
Sales EBITDA
In million €, ∆% yoy In million €, before special items
Key Messages
+28%
(+20% cpa)
EBITDA Margin before special items, cpa = currency and portfolio adjusted
36.3%
29.7%
+56%
HY1 2022: Crop Science
Sales growth rates in Key Messages cpa = currency and portfolio adjusted
• EyleaTM (+13%) driven by strong growth in
all regions
• XareltoTM (-6%) impacted by VBP driven
lower price and volumes in China as well as
loss of exclusivity in Brazil
• Strong performance of new products:
NubeqaTM sales nearly doubled, ongoing
dynamic launch momentum for KerendiaTM
• Higher costs from continued launch
investments and inflation weigh on margin
• Prior year earnings benefitted from sale of
priority review voucher
• FX effects dilute margin with 110 bp
2.907 2.867
H1'21 H1'22
8.859
9.442
H1'21 H1'22
Sales
In million €, ∆% yoy, cpa.
HY1 2022: Pharmaceuticals
Bayer Q2 2022 Investor Conference Call /// August 4th, 2022
20
Sales EBITDA
In million €, ∆% yoy In million €, before special items
Volume
+3%
Currency
+4%
Price
-1%
Portfolio
+0%
Key Messages
+7%
(+2% cpa)
30.4%
32.8%
EBITDA Margin before special items, cpa = currency and portfolio adjusted
-1%
Sales growth rates in Key Messages cpa = currency and portfolio adjusted
570
718
H1'21 H1'22
2.542
3.008
H1'21 H1'22
Sales
In million €, ∆% yoy, cpa.
HY1 2022: Consumer Health
Bayer Q2 2022 Investor Conference Call /// August 4th, 2022
21
Sales EBITDA
In million €, ∆% yoy In million €, before special items
Key Messages
Volume
+7%
Currency
+6%
Price
+5%
Portfolio
+1%
+18%
(+12% cpa)
23.9%
22.4%
EBITDA Margin before special items, cpa = currency and portfolio adjusted
+26%
• Allergy & Cold with exceptional rebound
(+28%) driven by high cold incidences
• Digestive Health (+14%) due to sustained
demand for MiraLAX in North America
• Nutritionals (+6%) continue growth
trajectory backed by preventive health trend
• Product line extension Bepanthen Dry Skin
contributes to Dermatology growth (+10%)
• Strong earnings leverage and margin
expansion despite cost increases
Sales growth rates in Key Messages cpa = currency and portfolio adjusted
HY1 2021 HY1 2022
Net Sales 23,182 27,458
EBITDAbefore special items 6,695 8,600
Special items -3,417 -657
Reported EBITDA 3,278 7,943
Depreciation & Amortization -2,476 -3,562
Reported EBIT 802 4,381
Amortization and impairment losses / loss reversals on
intangible assets
1,697 2,781
Special items (EBITDA) 3,417 657
Other 46 15
Core EBIT 5,962 7,834
Core financial result (before special items) -500 -984
Core EBT 5,462 6,850
Taxes (before special items) -1,327 -1,476
Core tax rate 24.3% 21.6%
Minorities -8 -12
Core Net income 4,127 5,362
No. of shares (m) 982.4 982.4
Core EPS (€) 4.20 5.46
Income from cont. Operations (after income taxes,
w/o non-controlling interest)
-246 2,993
Income from discont. Operations (after income taxes) 0 0
Net income -246 2,993
EPS from cont. and discont. Operations (€) -0.25 3.05
Delta Working Capital -2,602 -5,111
Operating Cash Flow (cont. operations) -768 1,378
Free cash flow -2,074 -47
CapEx and leasing, cont. Operations -822 -899
HY1 2022: Key KPIs Bayer Group
Bayer Q2 2022 Investor Conference Call /// August 4th, 2022
22
Guidance at ~23% for FY 2022
2
2
3
Reversal of Glyphosate Litigation Provision in Q2
2021 in Other WoC
3
Glyphosate Litigation Provision in Q2 2021,
additional PCB Litigation Provision in Q2 2022
1
1
HY1 2022: Key KPIs by Division
Bayer Q2 2022 Investor Conference Call /// August 4th, 2022
23
[€ million] HY1'21 HY1'22 HY1'21 HY1'22 HY1'21 HY1'22 HY1'21 HY1'22 HY1'21 HY1'22
Sales 11,667 14,908 8,859 9,442 2,542 3,008 114 100 23,182 27,458
Sales by region:
Europe / Middle East / Africa 2,884 3,388 3,469 3,713 852 953 113 99 7,318 8,153
North America 5,963 7,417 2,028 2,169 973 1,192 1 8,964 10,779
Asia / Pacific 1,142 1,328 2,915 3,085 423 490 1 4,481 4,903
Latin America 1,678 2,775 447 475 294 373 2,419 3,623
EBITDA -69 5,416 3,192 2,996 555 697 -400 -1,166 3,278 7,943
Special items -3,535 -2 285 129 -15 -21 -152 -763 -3,417 -657
EBITDA before special items 3,466 5,418 2,907 2,867 570 718 -248 -403 6,695 8,600
EBITDA margin before special items 29.7% 36.3% 32.8% 30.4% 22.4% 23.9% 28.9% 31.3%
EBIT -1,730 2,770 2,681 2,408 388 523 -537 -1,320 802 4,381
Special items -3,997 -1,324 277 38 -14 -21 -152 -764 -3,886 -2,071
EBIT before special items 2,267 4,094 2,404 2,370 402 544 -385 -556 4,688 6,452
EBIT margin before special items 19.4% 27.5% 27.1% 25.1% 15.8% 18.1% 20.2% 23.5%
Operating cash flow, continuing -2,403 164 1,381 1,059 406 429 -152 -274 -768 1,378
D&A and Write-downs 1,661 2,646 511 588 167 174 137 154 2,476 3,562
Employees at end of period 33,196 34,311 39,830 40,863 10,608 11,027 15,805 15,713 99,439 101,914
Group
Crop Science Pharmaceuticals Consumer Health Reconciliation
Innovation
24 Bayer Q2 2022 Investor Conference Call /// August 4th, 2022
Elimusertib (ATR Inhibitor) (BAY 1895344)
SLFN12 Complex-Inducer (BAY 2666605)
mEGFR Inhibitor (BAY 2927088)
HER2-TTC (HER2-Targeted Thorium Conjugate) (BAY 2701439)
Bapotulimab (ILDR2 fb Antibody) (BAY 1905254)
AhR Inhibitor (BAY 3176803)
Congestive Heart Failure Gene Therapy
sGC Activator 4 (BAY 3283142)
P2X4 Antagonist (BAY 2328065)
BDKRB1 Receptor Antagonist (BAY 2599210)
Peboctocogene Camaparvovec (FVIII Gene Therapy) (BAY 2599023)
Pompe Disease Gene Therapy
Parkinson‘s Disease Gene Therapy
Parkinson’s Disease Cell Therapy
sGC Activator 3 (BAY 1211163)
ADRA2C Antagonist (BAY 2925976)
Zabedosertib (IRAK4 Inhibitor) (BAY 1834845)
Regorafenib (combi Nivolumab) (BAY 734506)
/// Solid tumors (recurrent or metastatic)
Regorafenib (combi Pembrolizumab) (BAY 734506)
/// Hepatocellular Carcinoma (HCC)
Asundexian (FXIa Inhibitor) (BAY 2433334)
/// Stroke Prevention in Atrial Fibrillation (PACIFIC-AF)
/// 2⁰ Stroke Prevention (PACIFIC-STROKE)
/// Major Adverse Cardiac Events Prevention (PACIFIC-AMI)
Fesomersen (FXI-LICA) (BAY 2976217)
/// Thrombosis Prevention in ESRD (RE-THINC ESRD)
Osocimab (anti-FXIa Antibody) (BAY 1213790)
/// Thrombosis Prevention in ESRD (CONVERT ESRD)
Runcaciguat (sGC Activator) (BAY 1637108)
/// Chronic Kidney Disease (CKD) (CONCORD)
/// Non-prolif. Diabetic Retinopathy (NPDR) (NEON-NPDR)
Adrenomedullin Pegol (PEG-ADM) (BAY 1097761)
/// Acute Resp. Distress Syn. (ARDS) (SEAL TRIAL)
BDKRB1 Receptor Antagonist (BAY 2599210)
/// Neuropathic Pain (BRADiNP)
Gadoquatrane (High Relaxivity Contrast Agent) (BAY 1747846)
/// Magnetic Resonance Imaging (HRCA-PAT)
Darolutamide (AR Inhibitor)
/// Prostate Cancer (mHSPC) (ARANOTE)
/// Adjuvant Prostate Cancer (DASL-HiCaP)
Copanlisib (PI3K Inhibitor)
/// Non-Hodgkin Lymphoma (CHRONOS-4)
Regorafenib (multi-Kinase Inhibitor)
/// Glioblastoma (GBM AGILE)
Finerenone (MR Antagonist)
/// Heart Failure (HFmr/pEF) (FINEARTS-HF)
/// Non-diabetic CKD (FIND-CKD)
Vericiguat (sGC Stimulator)
/// Heart Failure (HFrEF) (VICTOR*)
Elinzanetant (Neurokinin-1,3 Rec Antagonist)
/// Vasomotor Symptoms (OASIS)
Aflibercept 8MG
/// Diabetic Macular Edema (DME) (PHOTON**)
/// Neovasc. Age-rel. Macular Degen. (nAMD) (PULSAR)
Phase III (10)
Phase II (12)
Phase I (17)
* Trial conducted by Merck & Co.
** Trial conducted by Regeneron Pharmaceuticals
Pharmaceuticals – Overview Development Portfolio (as of August 4th, 2022)
Bayer Q2 2022 Investor Conference Call /// August 4th, 2022
25
Pharmaceuticals –
R&D Developments since last Update on May 10, 2022
Bayer Q2 2022 Investor Conference Call /// August 4th, 2022
26
Phase I
• Discontinuation of ATA2271 (Mesothelin CAR-T Cell Therapy)
• Discontinuation of Mosliciguat (sGC Activator)
• Discontinuation of Enuvaptan (Vasopressin V1a Receptor Antagonist)
Kerendia (Finerenone)
• Approved in China to treat patients with chronic kidney disease associated with type 2 diabetes
(CKD/T2D)
Verquvo (Vericiguat)
• Approved in China to treat patients with chronic heart failure and reduced ejection fraction
(HFrEF)
27
Crop Science Division: R&D Pipeline (as of February 2022)
Phase I Phase II Phase III
CORN
SEED
&
TRAIT
€10-11bn
PSP
SOYBEAN
SEED
&
TRAIT
~€3bn
PSP
Seed Placement Digital Tool – NA
3rd Generation Insect Protection Trait
2nd Generation Soy Cyst Nematode resistance
- Breeding
Digital Disease Mgmt.
5th Generation Herbicide Tolerance Trait
(6 Tolerances – Adds PPO)
4th Generation Herbicide Tolerance Trait (HT4)
(5 Tolerances –Adds 2, 4-D and HPPD)
3 In collaboration with BASF 4 “Other” category includes seeds and traits, such as cotton, canola, wheat, OSR and sugarbeets, plus carbon and digital Models
VEGETABLES
and
OTHER
4
€6-7bn
PSP,
Including
Carbon
Model
Short Stature Corn – Biotech Trait3
5th Generation Herbicide Tolerance Trait
5th Generation Lepidoptera Protection Trait
4th Generation Coleoptera Protection Trait
4th Generation Herbicide Tolerance Trait w/ (RHS2)
Seed Density Digital Tool – EMEA
Seed Density Digital Tool – LATAM
Seed Density Digital Tool - NA
Seed Placement Digital Tool - NA
Corn Disease Shield Breeding - NA
Soybean Native Resistance - Breeding
Life Cycle Mgmt.1
2 In collaboration with KWS
Phase IV
Annual Germplasm Upgrades - Breeding
Annual Germplasm Upgrades – Breeding
.
Annual upgrades with new hybrids or varieties launching annually and
multiple generations in development.
PSP = Peak Sales Potential
Canola/OSR Digital Disease Mgmt. - NA Wheat Digital Disease Mgmt. - EMEA
Cotton 4th Generation Insect Protection Trait
Canola Dicamba Tolerant Trait
Sugarbeets 2nd Generation Herbicide
Tolerance Trait2
Lygus and Thrips Control Trait
(ThryvOn Technology) - Stewarded Commercial
Launch
Cotton 4th Generation Herbicide
Tolerance Trait (HT4)
(5 tolerances – Adds 2, HPPD and PPO)
Key Corn Seed & Traits, Soybean Seed & Traits and Other Projects with ~€19-€21bn Peak Sales Potential; ~50% Incremental
4th Generation Insect Protection Trait
Digital Disease Mgmt. – NA Short Stature Corn – Breeding Approach
4th Generation Lepidoptera Protection Trait
Wheat Annual Germplasm Upgrades - Breeding
Cotton Annual Germplasm Upgrades - Breeding
Canola/OSR Annual Germplasm Upgrades
- Breeding
Rice Annual Germplasm Upgrades - Breeding
Wheat Disease Package Upgrades - Breeding
Vegetables Annual Germplasm Upgrades
- Breeding
advanced to next phase
Projects listed here and included in the peak sales potential by segment do not include projects funded by our LEAPS investments
Bayer Q2 2022 Investor Conference Call /// August 4th, 2022
Crop Science Division: R&D Pipeline (as of February 2022)
28
Life Cycle Management1
1 Shown here is a subset of Bayer’s total life cycle management activities; focused on new formulation developments which have the potential to bring significant
innovation to customers compared to currently marketed product., Products shown may not yet be fully registered in all jurisdictions.
Non-Selective
Selective
Glyphosate LCM
Merlin Flexx / Adengo LCM
PSP = Peak Sales Potential
advanced to next phase
HERBICIDES ~€3bn PSP
FUNGICIDES ~€4bn PSP
INSECTICIDES ~€2bn PSP
SEEDGROWTH 2
Phase I Phase II Phase III
New AI Development
New Herbicide
New Herbicide
New Herbicide
(Post-Emergence Broad Acre)
Minuet/Serenade Soil Activ
New Biological Fungicide
New Fungicide New Fungicide for Asian Rust
iblon
Xivana
Novel Mite Solution
Plenexos
Cereals, oilseed rape, sugarbeets, cotton and rice
Fruits and vegetables
Soybeans
Corn
Phase IV
New Herbicide
Fox Supra
(Indiflin®)
New Biological Seed
Treatment
Key Crop Protection Projects with ~€9bn Peak Sales Potential; ~50% Incremental
Balance Flexx LCM
Convintro
Mateno Complete
Council Xtra
Council Star
Council One
Ronstar One
Mesosulfuron LCM
Luna Flexx
Super Nativo
Belt Smart
Velum LCM
Rice Plant Hopper
INS FUN ready mixture
Hombre successor
Redigo FS 25
New Fungicidal Seed
Treatment
Vayego Duo
Selection of projects listed here and included in the peak sales potential by segment do not include projects in early research or discovery
2 SeedGrowth is currently reported within other SBEs
Corvus LCM
Delaro Forte
Ibisio
Bayer Q2 2022 Investor Conference Call /// August 4th, 2022
Selected Examples of Recent Launches or Approvals
Consumer Health Division: Accelerating Growth with Innovation
29
Astepro Rx-to-OTC Switch
(launch in 2022)
 First OTC Steroid-Free Antihistamine
Nasal Spray approved in US, addressing
consumer unmet needs with
differentiated solution
AleveX Topical Pain Relief Solutions
(launched 2021)
 Expansion into a large and fast-growing
segment, offering superior consumer
experience
Bepanthen extension to Dry Skin
(launched 2021)
 Science-based innovation, solving high
consumer dissatisfaction
Bayer Q2 2022 Investor Conference Call /// August 4th, 2022

More Related Content

What's hot

MMX2022 - Le marché de la viande bovine dans le monde et en Europe en 2021-2022
MMX2022 - Le marché de la viande bovine dans le monde et en Europe en 2021-2022MMX2022 - Le marché de la viande bovine dans le monde et en Europe en 2021-2022
MMX2022 - Le marché de la viande bovine dans le monde et en Europe en 2021-2022Institut de l'Elevage - Idele
 
SUMMER TRAINING REPORT(final)
SUMMER TRAINING REPORT(final)SUMMER TRAINING REPORT(final)
SUMMER TRAINING REPORT(final)sakshi goyal
 
Quarterly analyst themes of oil and gas earnings, Q1 2022
Quarterly analyst themes of oil and gas earnings, Q1 2022Quarterly analyst themes of oil and gas earnings, Q1 2022
Quarterly analyst themes of oil and gas earnings, Q1 2022EY
 
CFA Institute Research Challenge - FINAL
CFA Institute Research Challenge - FINALCFA Institute Research Challenge - FINAL
CFA Institute Research Challenge - FINALMatt Kunke
 
The Bionic Future - Future Work Summit
The Bionic Future - Future Work SummitThe Bionic Future - Future Work Summit
The Bionic Future - Future Work SummitMiguel Carrasco
 
Merck presentation.
Merck presentation.Merck presentation.
Merck presentation.Bakryk
 
Project Report on Financial Statement Analysis
Project Report on Financial Statement AnalysisProject Report on Financial Statement Analysis
Project Report on Financial Statement Analysisarijitbhowmick
 
Diaporama fondamentaux du marché viande bovine - GEB Institut de l'Elevage
Diaporama fondamentaux du marché viande bovine - GEB Institut de l'ElevageDiaporama fondamentaux du marché viande bovine - GEB Institut de l'Elevage
Diaporama fondamentaux du marché viande bovine - GEB Institut de l'ElevageInstitut de l'Elevage - Idele
 
A REPORT ON FINANCIAL ANALYSIS OF DABUR AND BRITANNIA
A REPORT ON FINANCIAL ANALYSIS OF DABUR AND BRITANNIAA REPORT ON FINANCIAL ANALYSIS OF DABUR AND BRITANNIA
A REPORT ON FINANCIAL ANALYSIS OF DABUR AND BRITANNIAM Diable
 
Financial performance analysis
Financial performance analysisFinancial performance analysis
Financial performance analysisTalhaKhan255
 
Sommet 2022 Quelle offre française à l’export dans le contexte actuel de déca...
Sommet 2022 Quelle offre française à l’export dans le contexte actuel de déca...Sommet 2022 Quelle offre française à l’export dans le contexte actuel de déca...
Sommet 2022 Quelle offre française à l’export dans le contexte actuel de déca...Institut de l'Elevage - Idele
 
EY-commercial-excellence-in-pharma-3-0
EY-commercial-excellence-in-pharma-3-0EY-commercial-excellence-in-pharma-3-0
EY-commercial-excellence-in-pharma-3-0HealthiEx
 
GAL2023 - La Nouvelle-Zélande, une production laitière sous contraintes envir...
GAL2023 - La Nouvelle-Zélande, une production laitière sous contraintes envir...GAL2023 - La Nouvelle-Zélande, une production laitière sous contraintes envir...
GAL2023 - La Nouvelle-Zélande, une production laitière sous contraintes envir...Institut de l'Elevage - Idele
 
Health Experience: The difference between loyalty & leaving
Health Experience: The difference between loyalty & leavingHealth Experience: The difference between loyalty & leaving
Health Experience: The difference between loyalty & leavingaccenture
 
Bain & Co. GDRoadshow Presentation
Bain & Co. GDRoadshow PresentationBain & Co. GDRoadshow Presentation
Bain & Co. GDRoadshow PresentationGlassdoor
 
#BainWebinar Next Generation Industrial Performance Post COVID-19
#BainWebinar Next Generation Industrial Performance Post COVID-19#BainWebinar Next Generation Industrial Performance Post COVID-19
#BainWebinar Next Generation Industrial Performance Post COVID-19Bain & Company Brasil
 
GlaxoSmithKline GSK CH - A report on Business Strategy and Growth Avenues in ...
GlaxoSmithKline GSK CH - A report on Business Strategy and Growth Avenues in ...GlaxoSmithKline GSK CH - A report on Business Strategy and Growth Avenues in ...
GlaxoSmithKline GSK CH - A report on Business Strategy and Growth Avenues in ...Maneesh Garg
 

What's hot (20)

MMX2022 - Le marché de la viande bovine dans le monde et en Europe en 2021-2022
MMX2022 - Le marché de la viande bovine dans le monde et en Europe en 2021-2022MMX2022 - Le marché de la viande bovine dans le monde et en Europe en 2021-2022
MMX2022 - Le marché de la viande bovine dans le monde et en Europe en 2021-2022
 
SUMMER TRAINING REPORT(final)
SUMMER TRAINING REPORT(final)SUMMER TRAINING REPORT(final)
SUMMER TRAINING REPORT(final)
 
Quarterly analyst themes of oil and gas earnings, Q1 2022
Quarterly analyst themes of oil and gas earnings, Q1 2022Quarterly analyst themes of oil and gas earnings, Q1 2022
Quarterly analyst themes of oil and gas earnings, Q1 2022
 
CFA Institute Research Challenge - FINAL
CFA Institute Research Challenge - FINALCFA Institute Research Challenge - FINAL
CFA Institute Research Challenge - FINAL
 
The Bionic Future - Future Work Summit
The Bionic Future - Future Work SummitThe Bionic Future - Future Work Summit
The Bionic Future - Future Work Summit
 
Merck presentation.
Merck presentation.Merck presentation.
Merck presentation.
 
Ranbaxy
RanbaxyRanbaxy
Ranbaxy
 
Ratio Analysis
Ratio AnalysisRatio Analysis
Ratio Analysis
 
Project Report on Financial Statement Analysis
Project Report on Financial Statement AnalysisProject Report on Financial Statement Analysis
Project Report on Financial Statement Analysis
 
Diaporama fondamentaux du marché viande bovine - GEB Institut de l'Elevage
Diaporama fondamentaux du marché viande bovine - GEB Institut de l'ElevageDiaporama fondamentaux du marché viande bovine - GEB Institut de l'Elevage
Diaporama fondamentaux du marché viande bovine - GEB Institut de l'Elevage
 
A REPORT ON FINANCIAL ANALYSIS OF DABUR AND BRITANNIA
A REPORT ON FINANCIAL ANALYSIS OF DABUR AND BRITANNIAA REPORT ON FINANCIAL ANALYSIS OF DABUR AND BRITANNIA
A REPORT ON FINANCIAL ANALYSIS OF DABUR AND BRITANNIA
 
Financial performance analysis
Financial performance analysisFinancial performance analysis
Financial performance analysis
 
Sommet 2022 Quelle offre française à l’export dans le contexte actuel de déca...
Sommet 2022 Quelle offre française à l’export dans le contexte actuel de déca...Sommet 2022 Quelle offre française à l’export dans le contexte actuel de déca...
Sommet 2022 Quelle offre française à l’export dans le contexte actuel de déca...
 
EY-commercial-excellence-in-pharma-3-0
EY-commercial-excellence-in-pharma-3-0EY-commercial-excellence-in-pharma-3-0
EY-commercial-excellence-in-pharma-3-0
 
CEAt Finance ppt
CEAt Finance pptCEAt Finance ppt
CEAt Finance ppt
 
GAL2023 - La Nouvelle-Zélande, une production laitière sous contraintes envir...
GAL2023 - La Nouvelle-Zélande, une production laitière sous contraintes envir...GAL2023 - La Nouvelle-Zélande, une production laitière sous contraintes envir...
GAL2023 - La Nouvelle-Zélande, une production laitière sous contraintes envir...
 
Health Experience: The difference between loyalty & leaving
Health Experience: The difference between loyalty & leavingHealth Experience: The difference between loyalty & leaving
Health Experience: The difference between loyalty & leaving
 
Bain & Co. GDRoadshow Presentation
Bain & Co. GDRoadshow PresentationBain & Co. GDRoadshow Presentation
Bain & Co. GDRoadshow Presentation
 
#BainWebinar Next Generation Industrial Performance Post COVID-19
#BainWebinar Next Generation Industrial Performance Post COVID-19#BainWebinar Next Generation Industrial Performance Post COVID-19
#BainWebinar Next Generation Industrial Performance Post COVID-19
 
GlaxoSmithKline GSK CH - A report on Business Strategy and Growth Avenues in ...
GlaxoSmithKline GSK CH - A report on Business Strategy and Growth Avenues in ...GlaxoSmithKline GSK CH - A report on Business Strategy and Growth Avenues in ...
GlaxoSmithKline GSK CH - A report on Business Strategy and Growth Avenues in ...
 

Similar to Q2 2022 Investor Conference Call Presentation

Q3 2022 Investor Conference Call Presentation
Q3 2022 Investor Conference Call PresentationQ3 2022 Investor Conference Call Presentation
Q3 2022 Investor Conference Call PresentationBayer
 
Q1 2021 Investor Conference Call Presentation
Q1 2021 Investor Conference Call PresentationQ1 2021 Investor Conference Call Presentation
Q1 2021 Investor Conference Call PresentationBayer
 
Q3 2021 Investor Conference Call Presentation
Q3 2021 Investor Conference Call PresentationQ3 2021 Investor Conference Call Presentation
Q3 2021 Investor Conference Call PresentationBayer
 
FY/Q4 Investor Conference Call Presentation
FY/Q4 Investor Conference Call PresentationFY/Q4 Investor Conference Call Presentation
FY/Q4 Investor Conference Call PresentationBayer
 
Q1 2022 Investor Conference Call Presentation
Q1 2022 Investor Conference Call PresentationQ1 2022 Investor Conference Call Presentation
Q1 2022 Investor Conference Call PresentationBayer
 
Q2 2020 Investor Conference Call Presentation
Q2 2020 Investor Conference Call PresentationQ2 2020 Investor Conference Call Presentation
Q2 2020 Investor Conference Call PresentationBayer
 
Q2 2021 Investor Conference Call Presentation
Q2 2021 Investor Conference Call PresentationQ2 2021 Investor Conference Call Presentation
Q2 2021 Investor Conference Call PresentationBayer
 
BASF slides analyst conference - Full Year 2021
BASF slides analyst conference - Full Year 2021BASF slides analyst conference - Full Year 2021
BASF slides analyst conference - Full Year 2021BASF
 
Q3 2020 Investor Conference Call Presentation
Q3 2020 Investor Conference Call PresentationQ3 2020 Investor Conference Call Presentation
Q3 2020 Investor Conference Call PresentationBayer
 
Presentation BASF IR Conference FY 2022
Presentation BASF IR Conference FY 2022Presentation BASF IR Conference FY 2022
Presentation BASF IR Conference FY 2022BASF
 
Q1 2023 Investor Conference Call Presentation
Q1 2023 Investor Conference Call PresentationQ1 2023 Investor Conference Call Presentation
Q1 2023 Investor Conference Call PresentationBayer
 
Slides BASF Analyst Conference Q1 2022
Slides BASF Analyst Conference Q1 2022Slides BASF Analyst Conference Q1 2022
Slides BASF Analyst Conference Q1 2022BASF
 
Presentation for Bayer's Q1 2020 Investor Con-ference Call on April 27, 2020
Presentation for Bayer's Q1 2020 Investor Con-ference Call on April 27, 2020Presentation for Bayer's Q1 2020 Investor Con-ference Call on April 27, 2020
Presentation for Bayer's Q1 2020 Investor Con-ference Call on April 27, 2020Bayer
 
Slides Analyst Conference Q2 2022
Slides Analyst Conference Q2 2022Slides Analyst Conference Q2 2022
Slides Analyst Conference Q2 2022BASF
 
Q1 2019 Investor Conference Call Presentation
Q1 2019 Investor Conference Call PresentationQ1 2019 Investor Conference Call Presentation
Q1 2019 Investor Conference Call PresentationBayer
 
BASF slides analyst conference FY 2020
BASF slides analyst conference FY 2020BASF slides analyst conference FY 2020
BASF slides analyst conference FY 2020BASF
 
Barry Callebaut Group Half Year Results 2021/22 - Media & Analyst Presentation
Barry Callebaut Group Half Year Results 2021/22 - Media & Analyst PresentationBarry Callebaut Group Half Year Results 2021/22 - Media & Analyst Presentation
Barry Callebaut Group Half Year Results 2021/22 - Media & Analyst PresentationBarry Callebaut
 
Barry Callebaut Group – Full-Year Results, Fiscal Year 2020/21 - Media & Anal...
Barry Callebaut Group – Full-Year Results, Fiscal Year 2020/21 - Media & Anal...Barry Callebaut Group – Full-Year Results, Fiscal Year 2020/21 - Media & Anal...
Barry Callebaut Group – Full-Year Results, Fiscal Year 2020/21 - Media & Anal...Barry Callebaut
 
FY/Q4 2019 Investor Conference Call Presentation
FY/Q4 2019 Investor Conference Call PresentationFY/Q4 2019 Investor Conference Call Presentation
FY/Q4 2019 Investor Conference Call PresentationBayer
 
Slides BASF analyst conference Q2 2021
Slides BASF analyst conference Q2 2021Slides BASF analyst conference Q2 2021
Slides BASF analyst conference Q2 2021BASF
 

Similar to Q2 2022 Investor Conference Call Presentation (20)

Q3 2022 Investor Conference Call Presentation
Q3 2022 Investor Conference Call PresentationQ3 2022 Investor Conference Call Presentation
Q3 2022 Investor Conference Call Presentation
 
Q1 2021 Investor Conference Call Presentation
Q1 2021 Investor Conference Call PresentationQ1 2021 Investor Conference Call Presentation
Q1 2021 Investor Conference Call Presentation
 
Q3 2021 Investor Conference Call Presentation
Q3 2021 Investor Conference Call PresentationQ3 2021 Investor Conference Call Presentation
Q3 2021 Investor Conference Call Presentation
 
FY/Q4 Investor Conference Call Presentation
FY/Q4 Investor Conference Call PresentationFY/Q4 Investor Conference Call Presentation
FY/Q4 Investor Conference Call Presentation
 
Q1 2022 Investor Conference Call Presentation
Q1 2022 Investor Conference Call PresentationQ1 2022 Investor Conference Call Presentation
Q1 2022 Investor Conference Call Presentation
 
Q2 2020 Investor Conference Call Presentation
Q2 2020 Investor Conference Call PresentationQ2 2020 Investor Conference Call Presentation
Q2 2020 Investor Conference Call Presentation
 
Q2 2021 Investor Conference Call Presentation
Q2 2021 Investor Conference Call PresentationQ2 2021 Investor Conference Call Presentation
Q2 2021 Investor Conference Call Presentation
 
BASF slides analyst conference - Full Year 2021
BASF slides analyst conference - Full Year 2021BASF slides analyst conference - Full Year 2021
BASF slides analyst conference - Full Year 2021
 
Q3 2020 Investor Conference Call Presentation
Q3 2020 Investor Conference Call PresentationQ3 2020 Investor Conference Call Presentation
Q3 2020 Investor Conference Call Presentation
 
Presentation BASF IR Conference FY 2022
Presentation BASF IR Conference FY 2022Presentation BASF IR Conference FY 2022
Presentation BASF IR Conference FY 2022
 
Q1 2023 Investor Conference Call Presentation
Q1 2023 Investor Conference Call PresentationQ1 2023 Investor Conference Call Presentation
Q1 2023 Investor Conference Call Presentation
 
Slides BASF Analyst Conference Q1 2022
Slides BASF Analyst Conference Q1 2022Slides BASF Analyst Conference Q1 2022
Slides BASF Analyst Conference Q1 2022
 
Presentation for Bayer's Q1 2020 Investor Con-ference Call on April 27, 2020
Presentation for Bayer's Q1 2020 Investor Con-ference Call on April 27, 2020Presentation for Bayer's Q1 2020 Investor Con-ference Call on April 27, 2020
Presentation for Bayer's Q1 2020 Investor Con-ference Call on April 27, 2020
 
Slides Analyst Conference Q2 2022
Slides Analyst Conference Q2 2022Slides Analyst Conference Q2 2022
Slides Analyst Conference Q2 2022
 
Q1 2019 Investor Conference Call Presentation
Q1 2019 Investor Conference Call PresentationQ1 2019 Investor Conference Call Presentation
Q1 2019 Investor Conference Call Presentation
 
BASF slides analyst conference FY 2020
BASF slides analyst conference FY 2020BASF slides analyst conference FY 2020
BASF slides analyst conference FY 2020
 
Barry Callebaut Group Half Year Results 2021/22 - Media & Analyst Presentation
Barry Callebaut Group Half Year Results 2021/22 - Media & Analyst PresentationBarry Callebaut Group Half Year Results 2021/22 - Media & Analyst Presentation
Barry Callebaut Group Half Year Results 2021/22 - Media & Analyst Presentation
 
Barry Callebaut Group – Full-Year Results, Fiscal Year 2020/21 - Media & Anal...
Barry Callebaut Group – Full-Year Results, Fiscal Year 2020/21 - Media & Anal...Barry Callebaut Group – Full-Year Results, Fiscal Year 2020/21 - Media & Anal...
Barry Callebaut Group – Full-Year Results, Fiscal Year 2020/21 - Media & Anal...
 
FY/Q4 2019 Investor Conference Call Presentation
FY/Q4 2019 Investor Conference Call PresentationFY/Q4 2019 Investor Conference Call Presentation
FY/Q4 2019 Investor Conference Call Presentation
 
Slides BASF analyst conference Q2 2021
Slides BASF analyst conference Q2 2021Slides BASF analyst conference Q2 2021
Slides BASF analyst conference Q2 2021
 

More from Bayer

Q3 2023 Investor Webinar Presentation
Q3 2023 Investor Webinar PresentationQ3 2023 Investor Webinar Presentation
Q3 2023 Investor Webinar PresentationBayer
 
Q2 2023 Investor Webinar Presentation
Q2 2023 Investor Webinar PresentationQ2 2023 Investor Webinar Presentation
Q2 2023 Investor Webinar PresentationBayer
 
Investor Conference Call Presentation: Crop Science R&D Pipeline Update
Investor Conference Call Presentation:  Crop Science R&D Pipeline UpdateInvestor Conference Call Presentation:  Crop Science R&D Pipeline Update
Investor Conference Call Presentation: Crop Science R&D Pipeline UpdateBayer
 
Investor Conference Call Presentation: Bayer 2030 Sustainable Development Ob...
Investor Conference Call Presentation:  Bayer 2030 Sustainable Development Ob...Investor Conference Call Presentation:  Bayer 2030 Sustainable Development Ob...
Investor Conference Call Presentation: Bayer 2030 Sustainable Development Ob...Bayer
 
Q3 2019 Investor Conference Call Presentation
Q3 2019 Investor Conference Call PresentationQ3 2019 Investor Conference Call Presentation
Q3 2019 Investor Conference Call PresentationBayer
 
Crop Science Summer Technology Showcase August 1, 2019
Crop Science Summer Technology Showcase August 1, 2019Crop Science Summer Technology Showcase August 1, 2019
Crop Science Summer Technology Showcase August 1, 2019Bayer
 
Q2 2019 Investor Conference Call Presentation
Q2 2019 Investor Conference Call PresentationQ2 2019 Investor Conference Call Presentation
Q2 2019 Investor Conference Call PresentationBayer
 
FY/Q4 2018 Investor Conference Call Presentation
FY/Q4 2018 Investor Conference Call PresentationFY/Q4 2018 Investor Conference Call Presentation
FY/Q4 2018 Investor Conference Call PresentationBayer
 
Capital Markets Day in London - Investor Handout December 2018
Capital Markets Day in London - Investor Handout December 2018Capital Markets Day in London - Investor Handout December 2018
Capital Markets Day in London - Investor Handout December 2018Bayer
 
Q3 2018 Investor Conference Call Presentation
Q3 2018 Investor Conference Call PresentationQ3 2018 Investor Conference Call Presentation
Q3 2018 Investor Conference Call PresentationBayer
 
Q2 2018 Investor Conference Call Presentation
Q2 2018 Investor Conference Call PresentationQ2 2018 Investor Conference Call Presentation
Q2 2018 Investor Conference Call PresentationBayer
 
Q1 2018 Investor Conference Call Presentation
Q1 2018 Investor Conference Call PresentationQ1 2018 Investor Conference Call Presentation
Q1 2018 Investor Conference Call PresentationBayer
 
FY/Q4 2017 Investor Conference Call Presentation
FY/Q4 2017 Investor Conference Call PresentationFY/Q4 2017 Investor Conference Call Presentation
FY/Q4 2017 Investor Conference Call PresentationBayer
 
Q3 2017 Investor Conference Call Presentation
Q3 2017 Investor Conference Call PresentationQ3 2017 Investor Conference Call Presentation
Q3 2017 Investor Conference Call PresentationBayer
 
Q2 2017 Investor Conference Call Presentation
Q2 2017 Investor Conference Call PresentationQ2 2017 Investor Conference Call Presentation
Q2 2017 Investor Conference Call PresentationBayer
 
Q1 2017 Investor Conference Call Presentation
Q1 2017 Investor Conference Call PresentationQ1 2017 Investor Conference Call Presentation
Q1 2017 Investor Conference Call PresentationBayer
 
Meet Management in London - Investor Handout March 2017
Meet Management in London - Investor Handout March 2017Meet Management in London - Investor Handout March 2017
Meet Management in London - Investor Handout March 2017Bayer
 

More from Bayer (17)

Q3 2023 Investor Webinar Presentation
Q3 2023 Investor Webinar PresentationQ3 2023 Investor Webinar Presentation
Q3 2023 Investor Webinar Presentation
 
Q2 2023 Investor Webinar Presentation
Q2 2023 Investor Webinar PresentationQ2 2023 Investor Webinar Presentation
Q2 2023 Investor Webinar Presentation
 
Investor Conference Call Presentation: Crop Science R&D Pipeline Update
Investor Conference Call Presentation:  Crop Science R&D Pipeline UpdateInvestor Conference Call Presentation:  Crop Science R&D Pipeline Update
Investor Conference Call Presentation: Crop Science R&D Pipeline Update
 
Investor Conference Call Presentation: Bayer 2030 Sustainable Development Ob...
Investor Conference Call Presentation:  Bayer 2030 Sustainable Development Ob...Investor Conference Call Presentation:  Bayer 2030 Sustainable Development Ob...
Investor Conference Call Presentation: Bayer 2030 Sustainable Development Ob...
 
Q3 2019 Investor Conference Call Presentation
Q3 2019 Investor Conference Call PresentationQ3 2019 Investor Conference Call Presentation
Q3 2019 Investor Conference Call Presentation
 
Crop Science Summer Technology Showcase August 1, 2019
Crop Science Summer Technology Showcase August 1, 2019Crop Science Summer Technology Showcase August 1, 2019
Crop Science Summer Technology Showcase August 1, 2019
 
Q2 2019 Investor Conference Call Presentation
Q2 2019 Investor Conference Call PresentationQ2 2019 Investor Conference Call Presentation
Q2 2019 Investor Conference Call Presentation
 
FY/Q4 2018 Investor Conference Call Presentation
FY/Q4 2018 Investor Conference Call PresentationFY/Q4 2018 Investor Conference Call Presentation
FY/Q4 2018 Investor Conference Call Presentation
 
Capital Markets Day in London - Investor Handout December 2018
Capital Markets Day in London - Investor Handout December 2018Capital Markets Day in London - Investor Handout December 2018
Capital Markets Day in London - Investor Handout December 2018
 
Q3 2018 Investor Conference Call Presentation
Q3 2018 Investor Conference Call PresentationQ3 2018 Investor Conference Call Presentation
Q3 2018 Investor Conference Call Presentation
 
Q2 2018 Investor Conference Call Presentation
Q2 2018 Investor Conference Call PresentationQ2 2018 Investor Conference Call Presentation
Q2 2018 Investor Conference Call Presentation
 
Q1 2018 Investor Conference Call Presentation
Q1 2018 Investor Conference Call PresentationQ1 2018 Investor Conference Call Presentation
Q1 2018 Investor Conference Call Presentation
 
FY/Q4 2017 Investor Conference Call Presentation
FY/Q4 2017 Investor Conference Call PresentationFY/Q4 2017 Investor Conference Call Presentation
FY/Q4 2017 Investor Conference Call Presentation
 
Q3 2017 Investor Conference Call Presentation
Q3 2017 Investor Conference Call PresentationQ3 2017 Investor Conference Call Presentation
Q3 2017 Investor Conference Call Presentation
 
Q2 2017 Investor Conference Call Presentation
Q2 2017 Investor Conference Call PresentationQ2 2017 Investor Conference Call Presentation
Q2 2017 Investor Conference Call Presentation
 
Q1 2017 Investor Conference Call Presentation
Q1 2017 Investor Conference Call PresentationQ1 2017 Investor Conference Call Presentation
Q1 2017 Investor Conference Call Presentation
 
Meet Management in London - Investor Handout March 2017
Meet Management in London - Investor Handout March 2017Meet Management in London - Investor Handout March 2017
Meet Management in London - Investor Handout March 2017
 

Recently uploaded

Osisko Gold Royalties Ltd - Corporate Presentation, April 2024
Osisko Gold Royalties Ltd - Corporate Presentation, April 2024Osisko Gold Royalties Ltd - Corporate Presentation, April 2024
Osisko Gold Royalties Ltd - Corporate Presentation, April 2024Osisko Gold Royalties Ltd
 
Collective Mining | Corporate Presentation | April 2024
Collective Mining | Corporate Presentation | April 2024Collective Mining | Corporate Presentation | April 2024
Collective Mining | Corporate Presentation | April 2024CollectiveMining1
 
Mandalay Resources 2024 April IR Presentation
Mandalay Resources 2024 April IR PresentationMandalay Resources 2024 April IR Presentation
Mandalay Resources 2024 April IR PresentationMandalayResources
 
Investing in an initial public offering (IPO)
Investing in an initial public offering (IPO)Investing in an initial public offering (IPO)
Investing in an initial public offering (IPO)Shivam538298
 
Falcon Invoice Discounting unlock your cash flow potential
Falcon Invoice Discounting unlock your cash flow potentialFalcon Invoice Discounting unlock your cash flow potential
Falcon Invoice Discounting unlock your cash flow potentialAravindKumarChillapa
 
Corporate Presentation Probe April 2024.pdf
Corporate Presentation Probe April 2024.pdfCorporate Presentation Probe April 2024.pdf
Corporate Presentation Probe April 2024.pdfProbe Gold
 
Osisko Gold Royalties Ltd - Corporate Presentation, April 10, 2024
Osisko Gold Royalties Ltd - Corporate Presentation, April 10, 2024Osisko Gold Royalties Ltd - Corporate Presentation, April 10, 2024
Osisko Gold Royalties Ltd - Corporate Presentation, April 10, 2024Osisko Gold Royalties Ltd
 

Recently uploaded (9)

Osisko Gold Royalties Ltd - Corporate Presentation, April 2024
Osisko Gold Royalties Ltd - Corporate Presentation, April 2024Osisko Gold Royalties Ltd - Corporate Presentation, April 2024
Osisko Gold Royalties Ltd - Corporate Presentation, April 2024
 
Collective Mining | Corporate Presentation | April 2024
Collective Mining | Corporate Presentation | April 2024Collective Mining | Corporate Presentation | April 2024
Collective Mining | Corporate Presentation | April 2024
 
Mandalay Resources 2024 April IR Presentation
Mandalay Resources 2024 April IR PresentationMandalay Resources 2024 April IR Presentation
Mandalay Resources 2024 April IR Presentation
 
michang oil 003650 Algorithm Investment Report
michang oil 003650 Algorithm Investment Reportmichang oil 003650 Algorithm Investment Report
michang oil 003650 Algorithm Investment Report
 
Investing in an initial public offering (IPO)
Investing in an initial public offering (IPO)Investing in an initial public offering (IPO)
Investing in an initial public offering (IPO)
 
Falcon Invoice Discounting unlock your cash flow potential
Falcon Invoice Discounting unlock your cash flow potentialFalcon Invoice Discounting unlock your cash flow potential
Falcon Invoice Discounting unlock your cash flow potential
 
Korea District Heating Corporation 071320 Algorithm Investment Report
Korea District Heating Corporation 071320 Algorithm Investment ReportKorea District Heating Corporation 071320 Algorithm Investment Report
Korea District Heating Corporation 071320 Algorithm Investment Report
 
Corporate Presentation Probe April 2024.pdf
Corporate Presentation Probe April 2024.pdfCorporate Presentation Probe April 2024.pdf
Corporate Presentation Probe April 2024.pdf
 
Osisko Gold Royalties Ltd - Corporate Presentation, April 10, 2024
Osisko Gold Royalties Ltd - Corporate Presentation, April 10, 2024Osisko Gold Royalties Ltd - Corporate Presentation, April 10, 2024
Osisko Gold Royalties Ltd - Corporate Presentation, April 10, 2024
 

Q2 2022 Investor Conference Call Presentation

  • 1. /////////// Investor Conference Call Q2 2022 Results August 4th, 2022 Werner Baumann, CEO Wolfgang Nickl, CFO
  • 2. This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at http://www.bayer.com/. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. Guidance at constant currencies, not including portfolio divestitures if not mentioned differently. Cautionary Statements Regarding Forward-Looking Information Bayer Q2 2022 Investor Conference Call /// August 4th, 2022 2
  • 4. We Raise Our Guidance Based on Half Year Performance Bayer Q2 2022 Investor Conference Call /// August 4th, 2022 4 1 Growth Innovation 3 2 Resilience
  • 5. Gas Exposure and Mitigation Measures Bayer Q2 2022 Investor Conference Call /// August 4th, 2022 5 2nd Order Impact (INDIRECT) Own Operations (DIRECT) No material financial impact for FY 2022 expected 1 Including electricity, gas, coal, oil, utilities + steam Preparations to completely mitigate own gas exposure well advanced • Technical readiness to reduce natural gas dependency • Switch to alternative and renewable energy sources • Building up inventory where possible • Fixed contract pricing Systemic risk from disrupted operations of suppliers and contract manufacturers • Pro-active risk management to increase supply chain resilience Energy & Utilities Footprint 1 (2021) ~97% Other CoGS ~3% Energy Costs ~50% RoW EUR 450m1 ~35% ~15% Other EMEA
  • 6. /////////// Wolfgang Nickl, CFO Q2 2022 Results Group Performance & Outlook
  • 7. Sustained Growth and Earnings Dynamics in Q2 Bayer Q2 2022 Investor Conference Call /// August 4th, 2022 7 EBITDA 2.577 3.349 Q2'21 Q2'22 10.854 12.819 Q2'21 Q2'22 In million €, before special items In million €, ∆% yoy In €, Cont. Operations +18% (+10% cpa) +30% 26.1% 23.7% In million € Sales Core EPS Free Cash Flow EBITDA Margin before special items, cpa = currency and portfolio adjusted 1.152 1.140 Q2'21 Q2'22 1,61 1,93 Q2'21 Q2'22 +20% FX tailwind of €915m FX tailwind of €300m (+0.5%pts) -1% 2021 baseline incl. extraordinary gains in core financial result 2021 baseline incl. lower incentive payouts
  • 8. • Herbicides (+51%) with continued favorable market dynamics • Corn S&T (+10%) supported by the launch of high-performing new hybrids globally • Soy S&T (-16%) impacted by reduction of excess seed sales and exit of Argentina business; flat YTD on a comparable basis • Fungicides up (+4%), particularly in EMEA and LATAM • Substantially improved margin compared to low prior year basis 1.018 1.749 Q2'21 Q2'22 5.021 6.461 Q2'21 Q2'22 Sales In million €, ∆% yoy, cpa. Bayer Q2 2022 Investor Conference Call /// August 4th, 2022 8 Volume -2% Currency +12% Price +20% Portfolio 0% Sales EBITDA In million €, ∆% yoy In million €, before special items Key Messages +29% (+17% cpa) EBITDA Margin before special items, cpa = currency and portfolio adjusted 27.1% 20.3% +72% Crop Science: Continued Strong Growth Sales growth rates in Key Messages cpa = currency and portfolio adjusted
  • 9. • EyleaTM (+12%) with increases in all regions • XareltoTM (-6%) impacted by volume-based procurement in China and loss of exclusivity in Brazil • Strong performance of new products: NubeqaTM sales more than doubled, ongoing dynamic launch momentum for KerendiaTM • Continued investments in launches and roll-outs • Margin at constant currencies on par with prior year 1.409 1.478 Q2'21 Q2'22 4.494 4.818 Q2'21 Q2'22 Sales In million €, ∆% yoy, cpa. Pharmaceuticals: Driving Launch Products Bayer Q2 2022 Investor Conference Call /// August 4th, 2022 9 Sales EBITDA In million €, ∆% yoy In million €, before special items Volume +2% Currency +5% Price -0% Portfolio 0% Key Messages +7% (+2% cpa) 30.7% 31.4% EBITDA Margin before special items, cpa = currency and portfolio adjusted 5% Sales growth rates in Key Messages cpa = currency and portfolio adjusted
  • 10. 278 330 Q2'21 Q2'22 1.290 1.496 Q2'21 Q2'22 Sales In million €, ∆% yoy, cpa. Consumer Health: Sustained Growth Across All Regions Bayer Q2 2022 Investor Conference Call /// August 4th, 2022 10 Sales EBITDA In million €, ∆% yoy In million €, before special items Key Messages Volume +3% Currency +9% Price +4% Portfolio +1% +16% (+7% cpa) 22.1% 21.6% EBITDA Margin before special items, cpa = currency and portfolio adjusted +19% • Allergy & Cold (+17%) driven by higher number of cold incidences • AsteproTM launch preparation and trade inventory build up • Nutritionals (-4%) consolidate at very high level • Digestive Health (+13%) with sustained demand for MiraLAX in North America • Earnings benefitted from strong topline, continuous spending discipline and ability to pass on cost increases Sales growth rates in Key Messages cpa = currency and portfolio adjusted
  • 11. Sales Growth 2022 (cpa) EBITDA-margin 2022 (before special items) ~ 13% ~ 27% 3% - 4% ~ 32% 6% - 7% 22% - 23% FY 2022: Increased Outlook for Crop Science and Consumer Health Bayer Q2 2022 Investor Conference Call /// August 4th, 2022 11 Sales Growth 2022 (cpa) EBITDA-margin 2022 (before special items) Crop Science ~ 7% 25% - 26% Pharmaceuticals 3% - 4% ~ 32% Consumer Health 4% - 5% 22% - 23% cpa = currency and portfolio adjusted As of Mar ‘22 OLD As of Aug ‘22 NEW ES divestment effects not included; at constant currencies (based on 2021 average Actual rates)
  • 12. FY 2022: Group Outlook Raised Bayer Q2 2022 Investor Conference Call /// August 4th, 2022 12 Net Sales EBITDA margin (before special items) Core EPS Free cash flow Net financial debt ~ €46bn ~ 26% ~ €7.00 ~ €2.0 - €2.5bn2 ~ €33 - 34bn At constant currencies Estimated currency impact1 ~ + €3bn ~ + €0.40 ~ + €1.3bn ~ - 0.4%pts not material 1 Currency assumptions based on month-end June 2022 spot rates (1 EUR=) 1.04 USD, 5.42 BRL, 6.97 CNY, 141.63 JPY, 56.38 RUB. Impact calculated as difference to constant currencies. 2 Incl. net settlement payments of approx. -€2.5bn €47bn – €48bn 26 - 27% ~ €7.30 ~ €2.5bn2 ~ €33 - 34bn At constant currencies NEW (as of Aug ’22) OLD (as of Mar ’22) ES divestment effects not included; at constant currencies (based on 2021 average Actual rates)
  • 13. /////////// Investor Conference Call Q2 2022 Results August 4th, 2022 Werner Baumann, CEO Wolfgang Nickl, CFO
  • 14. FY 2022: Other Group KPIs Outlook Bayer Q2 2022 Investor Conference Call /// August 4th, 2022 14 Special items (EBITDA) Depreciation and amortization (clean) of which for intangible assets (clean) Core financial result Core tax rate Reconciliation (cEBITDA) ~ -€1.0bn ~ €3.6bn ~ €2.1bn ~ -€1.8bn ~ 23% ~ -€700m 1 Currency assumptions based on month-end June 2022 spot rates (1 EUR=) 1.04 USD, 5.42 BRL, 6.97 CNY, 141.63 JPY, 56.38 RUB. Impact calculated as difference to constant currencies ~ -€1.0bn ~ €3.6bn ~ €2.1bn ~ -€1.5bn ~ 23% ~ -€500m - -€600m NEW (as of Aug ’22) At constant currencies OLD (as of Mar ’22) Expected currency impacts:1 Not material At constant currencies ES divestment effects not included; at constant currencies (based on 2021 average Actual rates)
  • 15. Q2 2022: Core EPS to EPS Bridge Bayer Q2 2022 Investor Conference Call /// August 4th, 2022 15 in €
  • 16. Q2 2021 Q2 2022 Net Sales 10,854 12,819 EBITDAbefore special items 2,577 3,349 Special items -3,468 -698 Reported EBITDA -891 2,651 Depreciation & Amortization -1,390 -2,482 Reported EBIT -2,281 169 Amortization and impairment losses / loss reversals on intangible assets 1,025 2,082 Special items (EBITDA) 3,468 698 Other 3 7 Core EBIT 2,215 2,957 Core financial result (before special items) -115 -565 Core EBT 2,100 2,392 Taxes (before special items) -511 -490 Core tax rate 24.4% 20.6% Minorities -7 -9 Core Net income 1,582 1,893 No. of shares (m) 982.4 982.4 Core EPS (€) 1.61 1.93 Income from cont. Operations (after income taxes, w/o non-controlling interest) -2,335 -298 Income from discont. Operations (after income taxes) 0 0 Net income -2,335 -298 EPS from cont. and discont. Operations (€) -2.38 -0.30 Delta Working Capital 3,749 351 Operating Cash Flow (cont. operations) 1,997 2,104 Free cash flow 1,152 1,140 CapEx and leasing, cont. Operations -493 -550 Q2 2022: Key KPIs Bayer Group Bayer Q2 2022 Investor Conference Call /// August 4th, 2022 16 Guidance at ~23% for FY 2022 2 2 3 Reversal Glyphosate Litigation Provision in Other WoC in Q2 2021 3 Glyphosate Litigation Provision in Q2 2021, additional PCB Litigation Provision in Q2 2022 1 1
  • 17. Q2 2022: Key KPIs by Division Bayer Q2 2022 Investor Conference Call /// August 4th, 2022 17 [€ million] Q2'21 Q2'22 Q2'21 Q2'22 Q2'21 Q2'22 Q2'21 Q2'22 Q2'21 Q2'22 Sales 5,021 6,461 4,494 4,818 1,290 1,496 49 44 10,854 12,819 Sales by region: Europe / Middle East / Africa 1,003 1,255 1,774 1,878 419 462 49 44 3,245 3,639 North America 2,532 3,056 1,032 1,149 503 611 -1 1 4,066 4,817 Asia / Pacific 627 704 1,460 1,550 214 238 1 2,302 2,492 Latin America 859 1,446 228 241 154 185 0 -1 1,241 1,871 EBITDA -2,496 1,701 1,564 1,559 269 327 -228 -936 -891 2,651 Special items -3,514 -48 155 81 -9 -3 -100 -728 -3,468 -698 EBITDA before special items 1,018 1,749 1,409 1,478 278 330 -128 -208 2,577 3,349 EBITDA margin before special items 20.3% 27.1% 31.4% 30.7% 21.6% 22.1% • • 23.7% 26.1% EBIT -3,483 -258 1,312 1,206 187 239 -297 -1,018 -2,281 169 Special items -3,945 -1,369 152 -10 -8 -3 -100 -729 -3,901 -2,111 EBIT before special items 462 1,111 1,160 1,216 195 242 -197 -289 1,620 2,280 EBIT margin before special items 9.2% 17,2% 25.8% 25.2% 15.1% 16.2% • • 14.9% 17.8% Operating cash flow, continuing 1,734 2,551 570 35 165 116 -472 -598 1,997 2,104 D&A and Write-downs 987 1,959 252 353 82 88 69 82 1,390 2,482 Employees at end of period 33,196 34,311 39,830 40,863 10,608 11,027 15,805 15,713 99,439 101,914 Group Crop Science Pharmaceuticals Consumer Health Reconciliation
  • 18. HY1 2022: Group Overview Bayer Q2 2022 Investor Conference Call /// August 4th, 2022 18 EBITDA 6.695 8.600 HY1'21 HY1'22 23.182 27.458 HY1'21 HY1'22 In million €, before special items In million €, ∆% yoy In €, Cont. Operations +18% (+12% cpa) +29% 31.3% 28.9% In million € Sales Core EPS Free Cash Flow EBITDA Margin before special items, cpa = currency and portfolio adjusted -2.074 -47 HY1'21 HY1'22 4,20 5,46 HY1'21 HY1'22 +30% FX tailwind of €1,444m FX tailwind of €367m (-0.3%pts) Core Tax Rate below FY Significantly lower net settlement payouts
  • 19. • Double-digit sales growth across all regions • Herbicides (+56%) with stronger pricing in light of continued tight supply and strong demand for glyphosate-based herbicides • Corn S&T (+10%) supported by the launch of high-performing new hybrids globally • Soy S&T (-8%) impacted by reduction of excess seed sales and exit of Argentina soy business, flat YTD on a comparable basis • Fungicides (+12%) mostly driven by volume in EMEA and LATAM • Earnings benefitting as value-based pricing in a strong market and efficiency measures outpace significant cost inflation 3.466 5.418 H1'21 H1'22 11.667 14.908 H1'21 H1'22 Sales In million €, ∆% yoy, cpa. Bayer Q2 2022 Investor Conference Call /// August 4th, 2022 19 Volume +2% Currency +8% Price +18% Portfolio - Sales EBITDA In million €, ∆% yoy In million €, before special items Key Messages +28% (+20% cpa) EBITDA Margin before special items, cpa = currency and portfolio adjusted 36.3% 29.7% +56% HY1 2022: Crop Science Sales growth rates in Key Messages cpa = currency and portfolio adjusted
  • 20. • EyleaTM (+13%) driven by strong growth in all regions • XareltoTM (-6%) impacted by VBP driven lower price and volumes in China as well as loss of exclusivity in Brazil • Strong performance of new products: NubeqaTM sales nearly doubled, ongoing dynamic launch momentum for KerendiaTM • Higher costs from continued launch investments and inflation weigh on margin • Prior year earnings benefitted from sale of priority review voucher • FX effects dilute margin with 110 bp 2.907 2.867 H1'21 H1'22 8.859 9.442 H1'21 H1'22 Sales In million €, ∆% yoy, cpa. HY1 2022: Pharmaceuticals Bayer Q2 2022 Investor Conference Call /// August 4th, 2022 20 Sales EBITDA In million €, ∆% yoy In million €, before special items Volume +3% Currency +4% Price -1% Portfolio +0% Key Messages +7% (+2% cpa) 30.4% 32.8% EBITDA Margin before special items, cpa = currency and portfolio adjusted -1% Sales growth rates in Key Messages cpa = currency and portfolio adjusted
  • 21. 570 718 H1'21 H1'22 2.542 3.008 H1'21 H1'22 Sales In million €, ∆% yoy, cpa. HY1 2022: Consumer Health Bayer Q2 2022 Investor Conference Call /// August 4th, 2022 21 Sales EBITDA In million €, ∆% yoy In million €, before special items Key Messages Volume +7% Currency +6% Price +5% Portfolio +1% +18% (+12% cpa) 23.9% 22.4% EBITDA Margin before special items, cpa = currency and portfolio adjusted +26% • Allergy & Cold with exceptional rebound (+28%) driven by high cold incidences • Digestive Health (+14%) due to sustained demand for MiraLAX in North America • Nutritionals (+6%) continue growth trajectory backed by preventive health trend • Product line extension Bepanthen Dry Skin contributes to Dermatology growth (+10%) • Strong earnings leverage and margin expansion despite cost increases Sales growth rates in Key Messages cpa = currency and portfolio adjusted
  • 22. HY1 2021 HY1 2022 Net Sales 23,182 27,458 EBITDAbefore special items 6,695 8,600 Special items -3,417 -657 Reported EBITDA 3,278 7,943 Depreciation & Amortization -2,476 -3,562 Reported EBIT 802 4,381 Amortization and impairment losses / loss reversals on intangible assets 1,697 2,781 Special items (EBITDA) 3,417 657 Other 46 15 Core EBIT 5,962 7,834 Core financial result (before special items) -500 -984 Core EBT 5,462 6,850 Taxes (before special items) -1,327 -1,476 Core tax rate 24.3% 21.6% Minorities -8 -12 Core Net income 4,127 5,362 No. of shares (m) 982.4 982.4 Core EPS (€) 4.20 5.46 Income from cont. Operations (after income taxes, w/o non-controlling interest) -246 2,993 Income from discont. Operations (after income taxes) 0 0 Net income -246 2,993 EPS from cont. and discont. Operations (€) -0.25 3.05 Delta Working Capital -2,602 -5,111 Operating Cash Flow (cont. operations) -768 1,378 Free cash flow -2,074 -47 CapEx and leasing, cont. Operations -822 -899 HY1 2022: Key KPIs Bayer Group Bayer Q2 2022 Investor Conference Call /// August 4th, 2022 22 Guidance at ~23% for FY 2022 2 2 3 Reversal of Glyphosate Litigation Provision in Q2 2021 in Other WoC 3 Glyphosate Litigation Provision in Q2 2021, additional PCB Litigation Provision in Q2 2022 1 1
  • 23. HY1 2022: Key KPIs by Division Bayer Q2 2022 Investor Conference Call /// August 4th, 2022 23 [€ million] HY1'21 HY1'22 HY1'21 HY1'22 HY1'21 HY1'22 HY1'21 HY1'22 HY1'21 HY1'22 Sales 11,667 14,908 8,859 9,442 2,542 3,008 114 100 23,182 27,458 Sales by region: Europe / Middle East / Africa 2,884 3,388 3,469 3,713 852 953 113 99 7,318 8,153 North America 5,963 7,417 2,028 2,169 973 1,192 1 8,964 10,779 Asia / Pacific 1,142 1,328 2,915 3,085 423 490 1 4,481 4,903 Latin America 1,678 2,775 447 475 294 373 2,419 3,623 EBITDA -69 5,416 3,192 2,996 555 697 -400 -1,166 3,278 7,943 Special items -3,535 -2 285 129 -15 -21 -152 -763 -3,417 -657 EBITDA before special items 3,466 5,418 2,907 2,867 570 718 -248 -403 6,695 8,600 EBITDA margin before special items 29.7% 36.3% 32.8% 30.4% 22.4% 23.9% 28.9% 31.3% EBIT -1,730 2,770 2,681 2,408 388 523 -537 -1,320 802 4,381 Special items -3,997 -1,324 277 38 -14 -21 -152 -764 -3,886 -2,071 EBIT before special items 2,267 4,094 2,404 2,370 402 544 -385 -556 4,688 6,452 EBIT margin before special items 19.4% 27.5% 27.1% 25.1% 15.8% 18.1% 20.2% 23.5% Operating cash flow, continuing -2,403 164 1,381 1,059 406 429 -152 -274 -768 1,378 D&A and Write-downs 1,661 2,646 511 588 167 174 137 154 2,476 3,562 Employees at end of period 33,196 34,311 39,830 40,863 10,608 11,027 15,805 15,713 99,439 101,914 Group Crop Science Pharmaceuticals Consumer Health Reconciliation
  • 24. Innovation 24 Bayer Q2 2022 Investor Conference Call /// August 4th, 2022
  • 25. Elimusertib (ATR Inhibitor) (BAY 1895344) SLFN12 Complex-Inducer (BAY 2666605) mEGFR Inhibitor (BAY 2927088) HER2-TTC (HER2-Targeted Thorium Conjugate) (BAY 2701439) Bapotulimab (ILDR2 fb Antibody) (BAY 1905254) AhR Inhibitor (BAY 3176803) Congestive Heart Failure Gene Therapy sGC Activator 4 (BAY 3283142) P2X4 Antagonist (BAY 2328065) BDKRB1 Receptor Antagonist (BAY 2599210) Peboctocogene Camaparvovec (FVIII Gene Therapy) (BAY 2599023) Pompe Disease Gene Therapy Parkinson‘s Disease Gene Therapy Parkinson’s Disease Cell Therapy sGC Activator 3 (BAY 1211163) ADRA2C Antagonist (BAY 2925976) Zabedosertib (IRAK4 Inhibitor) (BAY 1834845) Regorafenib (combi Nivolumab) (BAY 734506) /// Solid tumors (recurrent or metastatic) Regorafenib (combi Pembrolizumab) (BAY 734506) /// Hepatocellular Carcinoma (HCC) Asundexian (FXIa Inhibitor) (BAY 2433334) /// Stroke Prevention in Atrial Fibrillation (PACIFIC-AF) /// 2⁰ Stroke Prevention (PACIFIC-STROKE) /// Major Adverse Cardiac Events Prevention (PACIFIC-AMI) Fesomersen (FXI-LICA) (BAY 2976217) /// Thrombosis Prevention in ESRD (RE-THINC ESRD) Osocimab (anti-FXIa Antibody) (BAY 1213790) /// Thrombosis Prevention in ESRD (CONVERT ESRD) Runcaciguat (sGC Activator) (BAY 1637108) /// Chronic Kidney Disease (CKD) (CONCORD) /// Non-prolif. Diabetic Retinopathy (NPDR) (NEON-NPDR) Adrenomedullin Pegol (PEG-ADM) (BAY 1097761) /// Acute Resp. Distress Syn. (ARDS) (SEAL TRIAL) BDKRB1 Receptor Antagonist (BAY 2599210) /// Neuropathic Pain (BRADiNP) Gadoquatrane (High Relaxivity Contrast Agent) (BAY 1747846) /// Magnetic Resonance Imaging (HRCA-PAT) Darolutamide (AR Inhibitor) /// Prostate Cancer (mHSPC) (ARANOTE) /// Adjuvant Prostate Cancer (DASL-HiCaP) Copanlisib (PI3K Inhibitor) /// Non-Hodgkin Lymphoma (CHRONOS-4) Regorafenib (multi-Kinase Inhibitor) /// Glioblastoma (GBM AGILE) Finerenone (MR Antagonist) /// Heart Failure (HFmr/pEF) (FINEARTS-HF) /// Non-diabetic CKD (FIND-CKD) Vericiguat (sGC Stimulator) /// Heart Failure (HFrEF) (VICTOR*) Elinzanetant (Neurokinin-1,3 Rec Antagonist) /// Vasomotor Symptoms (OASIS) Aflibercept 8MG /// Diabetic Macular Edema (DME) (PHOTON**) /// Neovasc. Age-rel. Macular Degen. (nAMD) (PULSAR) Phase III (10) Phase II (12) Phase I (17) * Trial conducted by Merck & Co. ** Trial conducted by Regeneron Pharmaceuticals Pharmaceuticals – Overview Development Portfolio (as of August 4th, 2022) Bayer Q2 2022 Investor Conference Call /// August 4th, 2022 25
  • 26. Pharmaceuticals – R&D Developments since last Update on May 10, 2022 Bayer Q2 2022 Investor Conference Call /// August 4th, 2022 26 Phase I • Discontinuation of ATA2271 (Mesothelin CAR-T Cell Therapy) • Discontinuation of Mosliciguat (sGC Activator) • Discontinuation of Enuvaptan (Vasopressin V1a Receptor Antagonist) Kerendia (Finerenone) • Approved in China to treat patients with chronic kidney disease associated with type 2 diabetes (CKD/T2D) Verquvo (Vericiguat) • Approved in China to treat patients with chronic heart failure and reduced ejection fraction (HFrEF)
  • 27. 27 Crop Science Division: R&D Pipeline (as of February 2022) Phase I Phase II Phase III CORN SEED & TRAIT €10-11bn PSP SOYBEAN SEED & TRAIT ~€3bn PSP Seed Placement Digital Tool – NA 3rd Generation Insect Protection Trait 2nd Generation Soy Cyst Nematode resistance - Breeding Digital Disease Mgmt. 5th Generation Herbicide Tolerance Trait (6 Tolerances – Adds PPO) 4th Generation Herbicide Tolerance Trait (HT4) (5 Tolerances –Adds 2, 4-D and HPPD) 3 In collaboration with BASF 4 “Other” category includes seeds and traits, such as cotton, canola, wheat, OSR and sugarbeets, plus carbon and digital Models VEGETABLES and OTHER 4 €6-7bn PSP, Including Carbon Model Short Stature Corn – Biotech Trait3 5th Generation Herbicide Tolerance Trait 5th Generation Lepidoptera Protection Trait 4th Generation Coleoptera Protection Trait 4th Generation Herbicide Tolerance Trait w/ (RHS2) Seed Density Digital Tool – EMEA Seed Density Digital Tool – LATAM Seed Density Digital Tool - NA Seed Placement Digital Tool - NA Corn Disease Shield Breeding - NA Soybean Native Resistance - Breeding Life Cycle Mgmt.1 2 In collaboration with KWS Phase IV Annual Germplasm Upgrades - Breeding Annual Germplasm Upgrades – Breeding . Annual upgrades with new hybrids or varieties launching annually and multiple generations in development. PSP = Peak Sales Potential Canola/OSR Digital Disease Mgmt. - NA Wheat Digital Disease Mgmt. - EMEA Cotton 4th Generation Insect Protection Trait Canola Dicamba Tolerant Trait Sugarbeets 2nd Generation Herbicide Tolerance Trait2 Lygus and Thrips Control Trait (ThryvOn Technology) - Stewarded Commercial Launch Cotton 4th Generation Herbicide Tolerance Trait (HT4) (5 tolerances – Adds 2, HPPD and PPO) Key Corn Seed & Traits, Soybean Seed & Traits and Other Projects with ~€19-€21bn Peak Sales Potential; ~50% Incremental 4th Generation Insect Protection Trait Digital Disease Mgmt. – NA Short Stature Corn – Breeding Approach 4th Generation Lepidoptera Protection Trait Wheat Annual Germplasm Upgrades - Breeding Cotton Annual Germplasm Upgrades - Breeding Canola/OSR Annual Germplasm Upgrades - Breeding Rice Annual Germplasm Upgrades - Breeding Wheat Disease Package Upgrades - Breeding Vegetables Annual Germplasm Upgrades - Breeding advanced to next phase Projects listed here and included in the peak sales potential by segment do not include projects funded by our LEAPS investments Bayer Q2 2022 Investor Conference Call /// August 4th, 2022
  • 28. Crop Science Division: R&D Pipeline (as of February 2022) 28 Life Cycle Management1 1 Shown here is a subset of Bayer’s total life cycle management activities; focused on new formulation developments which have the potential to bring significant innovation to customers compared to currently marketed product., Products shown may not yet be fully registered in all jurisdictions. Non-Selective Selective Glyphosate LCM Merlin Flexx / Adengo LCM PSP = Peak Sales Potential advanced to next phase HERBICIDES ~€3bn PSP FUNGICIDES ~€4bn PSP INSECTICIDES ~€2bn PSP SEEDGROWTH 2 Phase I Phase II Phase III New AI Development New Herbicide New Herbicide New Herbicide (Post-Emergence Broad Acre) Minuet/Serenade Soil Activ New Biological Fungicide New Fungicide New Fungicide for Asian Rust iblon Xivana Novel Mite Solution Plenexos Cereals, oilseed rape, sugarbeets, cotton and rice Fruits and vegetables Soybeans Corn Phase IV New Herbicide Fox Supra (Indiflin®) New Biological Seed Treatment Key Crop Protection Projects with ~€9bn Peak Sales Potential; ~50% Incremental Balance Flexx LCM Convintro Mateno Complete Council Xtra Council Star Council One Ronstar One Mesosulfuron LCM Luna Flexx Super Nativo Belt Smart Velum LCM Rice Plant Hopper INS FUN ready mixture Hombre successor Redigo FS 25 New Fungicidal Seed Treatment Vayego Duo Selection of projects listed here and included in the peak sales potential by segment do not include projects in early research or discovery 2 SeedGrowth is currently reported within other SBEs Corvus LCM Delaro Forte Ibisio Bayer Q2 2022 Investor Conference Call /// August 4th, 2022
  • 29. Selected Examples of Recent Launches or Approvals Consumer Health Division: Accelerating Growth with Innovation 29 Astepro Rx-to-OTC Switch (launch in 2022)  First OTC Steroid-Free Antihistamine Nasal Spray approved in US, addressing consumer unmet needs with differentiated solution AleveX Topical Pain Relief Solutions (launched 2021)  Expansion into a large and fast-growing segment, offering superior consumer experience Bepanthen extension to Dry Skin (launched 2021)  Science-based innovation, solving high consumer dissatisfaction Bayer Q2 2022 Investor Conference Call /// August 4th, 2022